40 Years Improving Global Health
With significant experience studying HIV, Ebola, Lassa fever, malaria, SARS-CoV-2, MERS-CoV, H1N1 influenza, Zika, and sepsis, HJF is especially well-positioned to expand collaborative research efforts in infectious diseases. Leveraging our extensive experience in international health and military medicine, HJF has helped build top-quality scientific and clinical teams at work against infectious disease threats worldwide.
From surveillance and epidemiology to vaccine development, HJF has become a key partner in infectious disease research within the military by promoting public-private partnerships and providing solutions to help DoD programs strengthen and diversify their research portfolios.
The Prophylaxis and Treatment of COVID-19 (PROTECT-APT) study is a multicenter trial comparing IPs to control in non-hospitalized adult SARS-CoV-2 infected patients and uninfected adult contacts of SARS-CoV-2 confirmed cases. The flexible platform trial design allows for the simultaneous evaluation of multiple investigational products and the ability to incorporate additional products as they become available. Enrollment commences in the fall of 2023.
By leveraging an existing longitudinal cohort study in the Military Heath System, the HJF-supported Infectious Diseases Clinical Research Program at USU provided major insights into the progression of SARS-CoV-2 infection, including clinical, virologic, and immunologic determinants of severe disease and long-term post-COVID conditions.
HJF Medical Research International and WRAIR are part of LEAP4WA, a unique multidisciplinary collaboration of seven leading research institutions in Africa, Europe, and North America to advance promising Lassa fever vaccine candidates.
HJFMRI supports the U.S. Army Medical Research Directorate-Africa’s (USAMRD-A) Infectious Disease Surveillance Program in Sub-Saharan Africa. This program implements infectious diseases surveillance, research and outbreak response activities across sub-Saharan African nations in collaboration with many partners.
HJFMRI, WRAIR and collaborators in Nigeria completed Monkeypox Public Outreach and Sample Collection Training in Lagos and Abuja in March and April, 2022. In October, they conducted training in Guinea, which had little prior infrastructure to support Monkeypox diagnostics.
We work in collaboration with military partners and other governmental and non-governmental global health institutions, including the Walter Reed Army Institute of Research (WRAIR), the Uniformed Services University of the Health Sciences (USU), the Naval Medical Research Center (NMRC), and U.S. Government civilian agencies.
Infectious diseases remain one of the greatest threats to mission capacity and operational readiness of U.S. military forces. In addition to posing a direct threat to service members, infectious diseases can impact international stability by weakening economies, military and police forces, and government and social institutions. HJF is a key partner driving infectious disease research success by promoting public-private partnerships and providing solutions to help strengthen and diversify DoD’s research portfolio to develop novel countermeasures for infectious diseases. Some of the infectious disease research programs HJF supports include:
- U.S. Military HIV Research Program at WRAIR
- Emerging Infectious Diseases Branch at WRAIR
- Austere environments Consortium for Enhanced Sepsis Outcomes at NMRC
- Infectious Diseases Clinical Research Program at USU
- Infectious Disease Surveillance with the U.S. Army Medical Research Directorate – Africa/Kenya (USAMRD-A)